BDF
TEVA icon

Balasa Dinverno & Foltz’s Teva Pharmaceuticals TEVA Stock Holding History

Balasa Dinverno & Foltz’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,100
Closed -$180K – 276
2020
Q1 		$180K Hold
20,100
– – 0.02% 235
2019
Q4 		$197K Hold
20,100
– – 0.02% 259
2019
Q3 		$138K Buy
+20,100
New +$154K 0.02% 245

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balasa Dinverno & Foltz's TEVA Position: Q2 2020 in Review

Balasa Dinverno & Foltz sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 20,100 shares — an estimated $180K sold.

Balasa Dinverno & Foltz first reported a position in TEVA in Q3 2019 and held it in 3 quarters. The position peaked at $197K in Q4 2019. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • Balasa Dinverno & Foltz reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 20,100 Teva Pharmaceuticals shares in Q2 2020, an estimated $180K.
  • Balasa Dinverno & Foltz first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Balasa Dinverno & Foltz's Teva Pharmaceuticals position peaked at $197K in Q4 2019.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Balasa Dinverno & Foltz's 13F filing for Q2 2020, filed 7 Aug 2020.